跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 2,561 条关于
“CTX-10726”
全部
2,561
临床试验
1,585
药物
657
机构
22
资讯
297
去年
Compass Therapeutics Reports Promising Clinical Data Across Bispecific Antibody Pipeline
去年
Compass Therapeutics Advances Pipeline with New Bispecific Antibody Candidate
9个月前
Compass Therapeutics Advances Oncology Pipeline with Pivotal Tovecimig Data Expected Q1 2026
8个月前
Compass Therapeutics Advances Multiple Bispecific Antibody Programs with Key Biliary Tract Cancer Data Expected Q1 2026
去年
Compass Therapeutics' CTX-471 Shows Promise with NCAM Biomarker Correlation in Advanced Malignancies
2年前
FDA Clears Path for Cingulate's CTx-1301 ADHD Treatment NDA Submission
去年
Compass Therapeutics Receives FDA Fast Track Designation for CTX-009 Bispecific Antibody
3年前
Cingulate's Phase 3 Trial Shows Promising Results for Once-Daily ADHD Treatment CTx-1301
去年
FDA Approves First Treatment for Cerebrotendinous Xanthomatosis (CTX), Offering Hope to Patients with Rare Genetic Disorder
去年
Cingulate's Once-Daily ADHD Drug CTx-1301 Shows Promising Safety Profile in Phase 3 Trials
第 1 页,共 30 页
上一页
下一页